Rekha Hemrajani - 17 Apr 2024 Form 4/A - Amendment Insider Report for BioAge Labs, Inc. (BIOA)

Source evidence Original filing metadata and source links for verification. 6 source fields
SEC form
4/A - Amendment
Accepted by SEC
10 Mar 2025, 16:11:28 UTC
Original report date
27 Sep 2024
Prior SEC filing
23 Jun 2023
Next SEC filing
13 Jun 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Dov A. Goldstein as attorney-in-fact

Key filing fact

Rekha Hemrajani filed Form 4/A - Amendment for BioAge Labs, Inc. (BIOA) on 10 Mar 2025.

Key facts

  • This page summarizes Rekha Hemrajani's Form 4/A - Amendment filing for BioAge Labs, Inc. (BIOA).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 10 Mar 2025, 16:11.

Change

  • Previous filing in this sequence was filed on 23 Jun 2023.
  • Current net transaction value: +$54,000.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIOA transaction

Common Stock

Purchase

Transaction value
$54,000
Shares
+3,000
Change %
Price
$18.00
Shares after
3,000
Date
27 Sep 2024
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The reported securities were purchased through a directed share program in connection with the Issuer's initial public offering.

SEC remarks

This Form 4 is being amended solely to report the purchase reflected in Table I above, which was inadvertently omitted from the Form 4 filed on September 27, 2024. The Form 4 filed on that date for the reporting person remains otherwise unmodified.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .